SG77243A1 - Ziprasidone formulations - Google Patents

Ziprasidone formulations

Info

Publication number: SG77243A1
Authority: SG; Singapore
Prior art keywords: ziprasidone; formulations; ziprasidone formulations
Prior art date: 1998-06-15

Application number

SG1999002794A

Other languages

English (en)

Inventor

Frank Robert Busch

Angela Carol Gatlin Hausberger

Bijan Rasadi

Daniel Ray Arenson

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-15

Filing date

1999-06-10

Publication date

2000-12-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG77243(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-06-10 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2000-12-19 Publication of SG77243A1 publication Critical patent/SG77243A1/en

Links

238000009472 formulation Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title 1
229960000607 ziprasidone Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Detergent Compositions (AREA)
Feeding Of Articles By Means Other Than Belts Or Rollers (AREA)
Polyamides (AREA)

SG1999002794A 1998-06-15 1999-06-10 Ziprasidone formulations SG77243A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US8922998P	1998-06-15	1998-06-15

Publications (1)

Publication Number	Publication Date
SG77243A1 true SG77243A1 (en)	2000-12-19

Family

ID=22216447

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG1999002794A SG77243A1 (en)	1998-06-15	1999-06-10	Ziprasidone formulations

Country Status (45)

Country	Link
US (1)	US6150366A (xx)
EP (1)	EP0965343B1 (xx)
JP (2)	JP3441676B2 (xx)
KR (1)	KR100338915B1 (xx)
CN (1)	CN1307994C (xx)
AP (1)	AP1216A (xx)
AR (1)	AR015553A1 (xx)
AT (1)	ATE240732T1 (xx)
AU (1)	AU753820B2 (xx)
BG (1)	BG64691B1 (xx)
BR (1)	BR9902268A (xx)
CA (1)	CA2274338C (xx)
CO (1)	CO5070579A1 (xx)
CY (1)	CY2003002I1 (xx)
CZ (1)	CZ297954B6 (xx)
DE (1)	DE69908021T2 (xx)
DK (1)	DK0965343T3 (xx)
EA (1)	EA002223B1 (xx)
ES (1)	ES2197581T3 (xx)
GT (1)	GT199900080A (xx)
HK (1)	HK1024184A1 (xx)
HN (1)	HN1999000089A (xx)
HR (1)	HRP990193B1 (xx)
HU (1)	HU226487B1 (xx)
ID (1)	ID23546A (xx)
IL (1)	IL130424A (xx)
IS (1)	IS2182B (xx)
MA (1)	MA26647A1 (xx)
MY (1)	MY121397A (xx)
NO (1)	NO316713B1 (xx)
NZ (1)	NZ336271A (xx)
OA (1)	OA11064A (xx)
PA (1)	PA8475601A1 (xx)
PE (1)	PE20000632A1 (xx)
PL (2)	PL195606B1 (xx)
PT (1)	PT965343E (xx)
RS (1)	RS49611B (xx)
SG (1)	SG77243A1 (xx)
SI (1)	SI0965343T1 (xx)
SK (1)	SK286245B6 (xx)
TR (1)	TR199901379A2 (xx)
TW (1)	TW590774B (xx)
UA (1)	UA59383C2 (xx)
UY (1)	UY25649A1 (xx)
ZA (1)	ZA993938B (xx)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080113025A1 (en) *	1998-11-02	2008-05-15	Elan Pharma International Limited	Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7175855B1 (en) *	1999-05-27	2007-02-13	Pfizer Inc.	Ziprasidone suspension
HUP0201297A3 (en) *	1999-05-27	2005-09-28	Pfizer Prod Inc	Ziprasidone suspension
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
HU230828B1 (en)	1999-10-29	2018-08-28	Euro Celtique Sa	Controlled release hydrocodone formulations
CN101317825A (zh)	2000-10-30	2008-12-10	欧罗赛铁克股份有限公司	控释氢可酮制剂
UY27668A1 (es) *	2002-02-20	2003-10-31	Pfizer Prod Inc	Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) *	2002-02-20	2004-03-11	Pfizer Inc.	Ziprasidone composition and synthetic controls
CN1320886C (zh)	2002-05-17	2007-06-13	杜克大学	安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
WO2004050655A1 (en) *	2002-12-04	2004-06-17	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride
AU2003300814A1 (en) *	2002-12-04	2004-06-23	Dr. Reddy's Laboratories Inc.	Polymorphic forms of ziprasidone and its hydrochloride
AU2003245027A1 (en) *	2003-04-11	2004-11-01	Hetero Drugs Limited	Novel crystalline forms of ziprasidone hydrochloride
DK2316456T3 (en) *	2003-04-29	2017-09-11	Orexigen Therapeutics Inc	Compositions for affecting weight loss comprising an opioid antagonist and bupropion
US7678799B2 (en) *	2003-06-03	2010-03-16	Teva Pharmaceutical Industries Ltd.	Crystalline ziprasidone HCl and processes for preparation thereof
US20050049295A1 (en) *	2003-06-12	2005-03-03	Dr. Reddy's Laboratories Limited	Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
EP1663166A2 (en) *	2003-09-02	2006-06-07	Imran Ahmed	Sustained release dosage forms of ziprasidone
EP1628973A2 (en) *	2003-10-24	2006-03-01	Teva Pharmaceutical Industries Ltd.	Processes for preparation of ziprasidone
WO2005054235A1 (en) *	2003-11-28	2005-06-16	Wockhardt Limited	Process for the preparing ziprasidone monohydrochloride hydrate
CA2550485A1 (en)	2003-12-18	2005-07-07	Teva Pharmaceutical Industries Ltd.	Polymorphic form b2 of ziprasidone base
US20050163858A1 (en) *	2003-12-31	2005-07-28	Garth Boehm	Ziprasidone formulations
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
EP1734955A2 (en) *	2004-01-13	2006-12-27	Duke University	Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
DE602005018171D1 (de) *	2004-02-27	2010-01-21	Ranbaxy Lab Ltd	Verfahren zur herstellung von ziprasidon
BRPI0510593A (pt) *	2004-05-03	2007-11-20	Univ Duke	composições para afetar a perda de peso
WO2005107719A2 (en) *	2004-05-06	2005-11-17	Sandoz Ag	Pharmaceutical composition comprising hydrophobic drug having improved solubility
CA2467538C (en) *	2004-05-14	2010-08-24	Apotex Pharmachem Inc.	New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US20070237828A1 (en) *	2004-06-11	2007-10-11	Dr. Reddy's Laboratories Limited	Ziprasidone Dosage Form
CA2471219A1 (en) *	2004-06-14	2005-12-14	Apotex Pharmachem Inc.	Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US9044503B2 (en) *	2004-08-27	2015-06-02	University Of Kentucky Research Foundation	Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
JP2008511607A (ja)	2004-08-31	2008-04-17	ファイザー・プロダクツ・インク	低溶解性薬物および重合体を含む医薬投与剤形
EP2623095A1 (en) *	2004-11-16	2013-08-07	Elan Pharma International Limited	Injectable nanoparticulate olanzapine formulations
WO2006085168A2 (en) *	2005-01-07	2006-08-17	Ranbaxy Laboratories Limited	Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
US7749529B2 (en) *	2005-02-08	2010-07-06	Ash Access Technology, Inc.	Catheter lock solution comprising citrate and a paraben
EP1863806A1 (en) *	2005-02-11	2007-12-12	Teva Pharmaceutical Industries Ltd	Amorphous ziprasidone mesylate
ITMI20050346A1 (it)	2005-03-07	2006-09-08	Dipharma Spa	Forma solida di ziprasidone cloridrato
CA2500667C (en) *	2005-03-11	2013-01-15	Apotex Pharmachem Inc.	Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006099452A1 (en) *	2005-03-14	2006-09-21	Teva Pharmaceutical Industries Ltd.	Anhydrous ziprasidone mesylate and a process for its preparation
CA2599391A1 (en) *	2005-03-14	2006-09-21	Teva Pharmaceutical Industries Ltd.	Crystalline forms of ziprasidone mesylate
NZ561950A (en) *	2005-04-13	2010-09-30	Pfizer Prod Inc	Injectable depot formulations comprising ziprasidone in nanoparticle form with two surface stabilizers
US20080305161A1 (en) *	2005-04-13	2008-12-11	Pfizer Inc	Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
GT200600161A (es) *	2005-04-22	2007-03-14		Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
ES2535478T3 (es)	2005-05-26	2015-05-12	Sumitomo Dainippon Pharma Co., Ltd.	Composición farmacéutica
MX2007016151A (es) *	2005-06-20	2008-03-06	Elan Pharma Int Ltd	Composiciones de liberacion controlada y en forma de nano-particulas que comprenden compuestos aril-heterociclicos.
CA2613474A1 (en) *	2005-06-20	2007-03-08	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
EP3132792B1 (en)	2005-11-22	2019-09-11	Nalpropion Pharmaceuticals, Inc.	Composition and methods for increasing insulin sensitivity
JP2009517394A (ja) *	2005-11-28	2009-04-30	オレキシジェン・セラピューティクス・インコーポレーテッド	ゾニサミドの徐放性製剤
PL379569A1 (pl) *	2006-04-28	2007-10-29	Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna	Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
EP1892243A1 (en) *	2006-08-02	2008-02-27	KRKA, tovarna zdravil, d.d., Novo mesto	Polymorphic forms of ziprasidone sulphate salts
EP1889844A3 (en) *	2006-08-02	2008-03-05	Krka	Polymorphic forms of ziprasidone sulphates
KR101654176B1 (ko)	2006-11-09	2016-09-09	오렉시젠 세러퓨틱스 인크.	신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
KR20170077291A (ko)	2006-11-09	2017-07-05	오렉시젠 세러퓨틱스 인크.	단위 용량 팩키지
CN101677568A (zh) *	2007-05-18	2010-03-24	赛多斯有限责任公司	齐拉西酮制剂
EP2197446A4 (en) *	2007-08-31	2012-01-25	Reddys Lab Ltd Dr	PREPARATION OF HYDROCHLORIDE OF ZIPRASIDONE MONOHYDRATE
US8410268B2 (en) *	2008-03-11	2013-04-02	Alkem Laboratories Limited	Process for the preparation of ziprasidone
JP2011521973A (ja)	2008-05-30	2011-07-28	オレキシジェン・セラピューティクス・インコーポレーテッド	内臓脂肪の状態を処置するための方法
DE102008045854A1 (de)	2008-09-05	2010-03-11	Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg	Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
JP5732453B2 (ja)	2009-06-25	2015-06-10	アルカーメスファーマアイルランドリミテッド	Ｎｈ酸性化合物のプロドラッグ
EP2340834A1 (en)	2009-12-30	2011-07-06	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Enhanced Solubility of Ziprasidone
AU2011203867B2 (en)	2010-01-11	2015-12-03	Nalpropion Pharmaceuticals Llc	Methods of providing weight loss therapy in patients with major depression
EP3662899A1 (en)	2010-02-25	2020-06-10	Bristol-Myers Squibb Holdings Ireland Unlimited Company	Apixaban formulations
US20130108701A1 (en)	2010-05-25	2013-05-02	Krishna Murthy Bhavanasi	Solid Dosage Forms of Antipsychotics
SI23610A (sl)	2011-01-13	2012-07-31	Diagen@d@o@o	Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
ES2802048T3 (es)	2012-06-06	2021-01-15	Nalpropion Pharmaceuticals Llc	Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular
WO2014078568A1 (en)	2012-11-14	2014-05-22	The Johns Hopkins University	Methods and compositions for treating schizophrenia
US11273158B2 (en)	2018-03-05	2022-03-15	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5264446A (en) *	1980-09-09	1993-11-23	Bayer Aktiengesellschaft	Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) *	1987-03-02	1994-02-23	Pfizer	Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) *	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) *	1988-01-22	1989-11-28	Pfizer Inc.	Piperazinyl-heterocyclic compounds
DE4141268A1 (de) *	1991-12-14	1993-06-17	Merck Patent Gmbh	Pharmazeutische zubereitung
US5312925A (en) *	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5338846A (en) *	1992-08-26	1994-08-16	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5206366A (en) *	1992-08-26	1993-04-27	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) *	1993-06-28	1994-10-25	Pfizer Inc.	Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DK0790236T3 (da) *	1996-02-13	2004-02-23	Pfizer	Prolægemidler af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-on
ATE364374T1 (de) *	1997-08-11	2007-07-15	Pfizer Prod Inc	Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit

1999
- 1999-05-27 US US09/320,985 patent/US6150366A/en not_active Expired - Lifetime
- 1999-06-04 HN HN1999000089A patent/HN1999000089A/es unknown
- 1999-06-08 DE DE69908021T patent/DE69908021T2/de not_active Withdrawn - After Issue
- 1999-06-08 GT GT199900080A patent/GT199900080A/es unknown
- 1999-06-08 EP EP99304451A patent/EP0965343B1/en not_active Expired - Lifetime
- 1999-06-08 SI SI9930316T patent/SI0965343T1/xx unknown
- 1999-06-08 AT AT99304451T patent/ATE240732T1/de active
- 1999-06-08 PT PT99304451T patent/PT965343E/pt unknown
- 1999-06-08 ES ES99304451T patent/ES2197581T3/es not_active Expired - Lifetime
- 1999-06-08 DK DK99304451T patent/DK0965343T3/da active
- 1999-06-09 SK SK769-99A patent/SK286245B6/sk not_active IP Right Cessation
- 1999-06-09 TW TW088109645A patent/TW590774B/zh not_active IP Right Cessation
- 1999-06-09 AU AU33983/99A patent/AU753820B2/en not_active Ceased
- 1999-06-10 SG SG1999002794A patent/SG77243A1/en unknown
- 1999-06-10 IL IL13042496A patent/IL130424A/xx not_active IP Right Cessation
- 1999-06-10 AP APAP/P/1999/001579A patent/AP1216A/en active
- 1999-06-11 AR ARP990102822A patent/AR015553A1/es active IP Right Grant
- 1999-06-11 IS IS5079A patent/IS2182B/is unknown
- 1999-06-11 PE PE1999000523A patent/PE20000632A1/es not_active Application Discontinuation
- 1999-06-11 MY MYPI99002412A patent/MY121397A/en unknown
- 1999-06-11 CA CA002274338A patent/CA2274338C/en not_active Expired - Lifetime
- 1999-06-11 TR TR1999/01379A patent/TR199901379A2/xx unknown
- 1999-06-14 JP JP16677399A patent/JP3441676B2/ja not_active Expired - Lifetime
- 1999-06-14 RS YUP-271/99A patent/RS49611B/sr unknown
- 1999-06-14 CZ CZ0212799A patent/CZ297954B6/cs not_active IP Right Cessation
- 1999-06-14 BG BG103489A patent/BG64691B1/bg unknown
- 1999-06-14 MA MA25621A patent/MA26647A1/fr unknown
- 1999-06-14 PA PA19998475601A patent/PA8475601A1/es unknown
- 1999-06-14 HU HU9901960A patent/HU226487B1/hu not_active IP Right Cessation
- 1999-06-14 UA UA99063279A patent/UA59383C2/uk unknown
- 1999-06-14 ZA ZA9903938A patent/ZA993938B/xx unknown
- 1999-06-14 PL PL380276A patent/PL195606B1/pl not_active IP Right Cessation
- 1999-06-14 HR HR990193A patent/HRP990193B1/xx not_active IP Right Cessation
- 1999-06-14 NO NO19992892A patent/NO316713B1/no not_active IP Right Cessation
- 1999-06-14 CN CNB991111192A patent/CN1307994C/zh not_active Expired - Fee Related
- 1999-06-14 NZ NZ336271A patent/NZ336271A/xx not_active IP Right Cessation
- 1999-06-14 KR KR1019990021977A patent/KR100338915B1/ko not_active IP Right Cessation
- 1999-06-14 PL PL333737A patent/PL195209B1/pl not_active IP Right Cessation
- 1999-06-14 ID IDP990571D patent/ID23546A/id unknown
- 1999-06-14 OA OA9900126A patent/OA11064A/en unknown
- 1999-06-15 CO CO99037319A patent/CO5070579A1/es unknown
- 1999-06-15 EA EA199900467A patent/EA002223B1/ru not_active IP Right Cessation
- 1999-06-15 BR BR9902268-0A patent/BR9902268A/pt not_active Application Discontinuation
- 1999-08-10 UY UY25649A patent/UY25649A1/es unknown
2000
- 2000-06-16 HK HK00103630A patent/HK1024184A1/xx not_active IP Right Cessation
2001
- 2001-06-11 JP JP2001175276A patent/JP4187423B2/ja not_active Expired - Lifetime
2003
- 2003-11-20 CY CY200300002C patent/CY2003002I1/el unknown

Also Published As

Publication number	Publication date
NZ336271A (en)	2000-10-27
EA199900467A3 (ru)	2000-04-24
EA199900467A2 (ru)	1999-12-29
CZ212799A3 (cs)	2000-09-13
HU226487B1 (en)	2009-03-02
NO992892L (no)	1999-12-16
JP4187423B2 (ja)	2008-11-26
CN1307994C (zh)	2007-04-04
RS49611B (sr)	2007-06-04
ZA993938B (en)	2000-12-14
BG103489A (en)	2000-07-31
HRP990193A2 (en)	2000-02-29
CO5070579A1 (es)	2001-08-28
PL195209B1 (pl)	2007-08-31
GT199900080A (es)	2000-11-29
JP2002003492A (ja)	2002-01-09
BR9902268A (pt)	2000-05-02
UY25649A1 (es)	2000-02-23
SK76999A3 (en)	2000-12-11
PT965343E (pt)	2003-08-29
EP0965343B1 (en)	2003-05-21
CZ297954B6 (cs)	2007-05-09
AU753820B2 (en)	2002-10-31
EP0965343A3 (en)	2000-02-23
IS2182B (is)	2006-12-15
DE69908021T2 (de)	2003-11-27
EP0965343A2 (en)	1999-12-22
JP2000007566A (ja)	2000-01-11
ATE240732T1 (de)	2003-06-15
AP1216A (en)	2003-10-19
HUP9901960A2 (hu)	2000-08-28
JP3441676B2 (ja)	2003-09-02
AP9901579A0 (en)	1999-06-30
ES2197581T3 (es)	2004-01-01
DE69908021D1 (de)	2003-06-26
PL195606B1 (pl)	2007-10-31
PA8475601A1 (es)	2000-09-29
AU3398399A (en)	1999-12-23
BG64691B1 (bg)	2005-12-30
CN1242987A (zh)	2000-02-02
NO316713B1 (no)	2004-04-13
HN1999000089A (es)	1999-11-03
OA11064A (en)	2002-03-13
SI0965343T1 (en)	2003-10-31
PE20000632A1 (es)	2000-07-26
DK0965343T3 (da)	2003-08-04
AR015553A1 (es)	2001-05-02
CA2274338C (en)	2003-04-15
KR20000006143A (ko)	2000-01-25
EA002223B1 (ru)	2002-02-28
US6150366A (en)	2000-11-21
TW590774B (en)	2004-06-11
IS5079A (is)	1999-12-16
IL130424A (en)	2003-10-31
CA2274338A1 (en)	1999-12-15
YU27199A (sh)	2002-12-10
UA59383C2 (uk)	2003-09-15
PL333737A1 (en)	1999-12-20
MY121397A (en)	2006-01-28
TR199901379A2 (xx)	2000-01-21
CY2003002I1 (el)	2009-11-04
KR100338915B1 (ko)	2002-05-30
SK286245B6 (sk)	2008-06-06
HU9901960D0 (en)	1999-08-30
HUP9901960A3 (en)	2000-09-28
ID23546A (id)	2000-05-04
HK1024184A1 (en)	2000-10-05
HRP990193B1 (en)	2003-08-31
IL130424A0 (en)	2000-06-01
NO992892D0 (no)	1999-06-14
MA26647A1 (fr)	2004-12-20

Publication	Publication Date	Title
AP9901579A0 (en)	1999-06-30	Ziprasidone formulations
GB9804013D0 (en)	1998-04-22	Formulations
EP1113799A4 (en)	2004-06-09	PROTEIN-BASED PREPARATION
GB9715751D0 (en)	1997-10-01	Formulations
EP1107735A4 (en)	2002-05-15	FORMULATION OF OMEPRAZOLE
GB0014805D0 (en)	2000-08-09	Glassbreaker (2)
GB9806312D0 (en)	1998-05-20	Novel formulations
GB9815002D0 (en)	1998-09-09	Formulations
EP1148957A4 (en)	2005-06-15	GUIDE WIRE
GB9815001D0 (en)	1998-09-09	Formulations
GB9810181D0 (en)	1998-07-08	Novel formulations
GB9901323D0 (en)	1999-03-10	Freeface 1
EG24008A (en)	2008-03-19	Ziprasidone formulations
GB9916299D0 (en)	1999-09-15	Dogex 1
GB0028459D0 (en)	2001-01-10	Glor 2
GB9910118D0 (en)	1999-06-30	Formulations
GB9810143D0 (en)	1998-07-08	Parasiticidal formulations
GB9909079D0 (en)	1999-06-16	Novel formulations
GB9909080D0 (en)	1999-06-16	Novel formulations
GB9720228D0 (en)	1997-11-26	Parasiticidal formulations
GB9823645D0 (en)	1998-12-23	Formulation
SI1119359T1 (en)	2004-12-31	2-methyl-thieno-benzodiazepine formulation
GB9704521D0 (en)	1997-04-23	Formulations
GB9703101D0 (en)	1997-04-02	Formulations
GB9703100D0 (en)	1997-04-02	Formulations